Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fasinumab

Deal Watch June 2016

Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

- PMLiVE

Teva suspends migraine patch on burn reports

FDA issues safety alert and instigates investigation into Zecuity

- PMLiVE

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Recommends long-acting opioid analgesics Troxyca ER and Vantrela ER for approval

Teva Pharma logo

FDA turns down Teva’s Huntington’s disease drug

Has requested further analysis on certain metabolites of the chorea candidate

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

FDA approves new drugs from Teva, Lilly and Elusys

Cinqair, Taltz and Anthim have all been given the green light in the US

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links